SUMMARY The purpose of our study was to evaluate the effect of somatostatin (500 ,g/h intravenously) upon insulin, c-peptide, glucagon and plasma amino acids concentrations in patients with and without cirrhosis of the liver. The typical plasma amino acid pattern in cirrhosis is characterised by increased concentrations of the aromatic amino acids and decreased concentrations of the branched chain amino acids and of alanine and glycine. After administration of somatostatin insulin, c-peptide and glucagon concentrations decreased and those of the branched chain amino acids in both groups increased; in addition in patients with cirrhosis the plasma concentrations of threonine, serine, glycine, alanine, lysine, and arginine increased also. Infusion of somatostatin plus insulin in patients with cirrhosis succeeded in preventing the increase in the branched chain amino acid concentrations, while the infusion of somatostatin plus glucagon decreased threonine, serine, glycine, alinine, phenylalanine, tyrosine, lysine and arginine concentrations. It is therefore suggested that the effect of somatostatin on the plasma amino acids may be because of the reduction of insulin and glucagon concentrations; however, other effects of somatostatin cannot be excluded at present.
The existence of an altered amino acid pattern in the plasma of patients with advanced cirrhosis of the liver is well known. This pattern is characterised by an increase in the concentration of the aromatic amino acids tyrosine and phenylalanine and a decrease in the concentrations of the branched chain amino acids valine, leucine, isoleucine and of alanine and glycine. [1] [2] [3] [4] 
Results
In patients with cirrhosis of the liver the preinfusion concentrations of insulin and glucagon (Table 1) and of the aromatic amino acids tyrosine and phenylalanine were raised whereas the concentrations of the branched chain amino acids valine, leucine, isoleucine and of alanine and glycine were decreased when compared with controls (Table 2) . No differences were seen in the concentration of c-peptide (Table 1) .
Somatostatin infusion resulted in a significant decrease of insulin, glucagon and c-peptide concentration in both groups (Table 1) . At the end of somatostatin infusion the concentration of the branched chain amino acids were significantly increased in both groups, while the concentrations of the aromatic amino acids remained unchanged ( Table 2 ). In contrast with the controls somatostatin had an additional effect on the so called gluconeogenic amino acids threonine, serine, glycine, alanine, lysine, and arginine in patients with cirrhosis of the liver. Infusion of somatostatin led to a significant increase of these amino acids. The most prominent rise induced by somatostatin concerned the concentration of alanine, which reached normal values ( Table 2 ). The combination of somatostatin and glucagon in patients with cirrhosis led to a decrease of insulin from 230±70 to 79±40 pmol/l and of c-peptide from 0-6±0-22 to 0-1±0-05 nmol/l (p<0.01), whereas the concentration of glucagon increased from 71±7 to 229±28 pmol/l (p<0.001). In addition, the increase of the gluconeogenic amino acids induced by Table 2 Plasma amino acids (,umolll) in control and cirrhotic patients before and after infusion ofsomatostatin (500 ,uglh after a bolus injection of250 ,ug) for 240 minutes Controls (10) Cirrhotics (10) Correction of altered plasma amino acid pattern in cirrhosis of the liver by somatostatin somatostatin alone was not observed. In contrast the concentrations of the gluconeogenic and aromatic amino acids decreased significantly (Table 3) . Infusion of somatostatin plus insulin led to a decrease of glucagon from 63±2-8 to 45±5 pmol/l and of c-peptide from 065±02 to 01±0-05 nmol/l (p<0-01), but the insulin concentrations remained raised (129±21 pmol/l). No increase of the branched chain amino acids was observed.
Discussion
In patients with cirrhosis of the liver high insulin concentrations were increased and c-peptide concentrations were normal. In both groups of patients (those with and without cirrhosis) the infusion of somatostatin initially resulted in a marked reduction of insulin and c-peptide concentrations. After the somatostatin infusion, insulin levels nonetheless remained raised in the patients with cirrhosis, while the c-peptide concentrations Glucagon concentrations are raised in advanced cirrhosis of the liver resulting from an increase of the so called pancreatic glucagon.21 In controls and in patients with cirrhosis glucagon concentrations were reduced by somatostatin, but the concentrations remained raised in the cirrhotic subjects. It is known that glucagon is degraded in the liver but substantial metabolism occurs in the kidneys as well. 22 Under the influence of somatostatin a normal glucagon concentration could therefore be expected in cirrhotics, as somatostatin inhibits the pancreatic secretion of the hormone." The failure of somatostatin to reduce raised glucagon concentrations to normal may be caused by an altered secretion of the hormone as suggested by Sherwin et al. 23 Infusion of somatostatin improved in part the deranged plasma amino acid pattern in cirrhosis in that the concentrations of the branched chain amino acids and of threonine, serine, glycine alanine, lysine, and arginine increased. The increase of the gluconeogenic amino acids may be because of the reduction of hepatic uptake and metabolism by the liver when glucagon concentrations are lowered by somatostatin, as it has been shown that suppression of glucagon secretion impairs hepatic extraction of these amino acids. 24 The concomitant infusion of somatostatin and glucagon led to a decrease of the insulin/glucagon ratio from 3 55 to 0-34 in patients with cirrhosis; this reduced insulin/glucagon ratio would favour the movement of plasma amino acids into the gluconeogenic pathways25 and may therefore be responsible for the resulting decrease in plasma amino acid concentrations. It is notable that the rise in plasma glucagon concentrations during the infusion of somatostatin plus glucagon also decreased the aromatic amino acid concentrations. These results suggest that hyperglucagonaemia may not be responsible for the increased concentrations of the aromatic amino acids as suggested by James et al. 9 Our interpretation is in accordance with data from the literature which have shown that glucagon stimulated the metabolism of the aromatic amino acids26 and induced hypoaminoacidaemia. [27] [28] [29] The combined infusion of somatostatin plus insulin in cirrhosis prevented the increase of the branched chain amino acids normally associated with somatostatin administration. It 
